Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for Foot Dystonia-associated Pain in Parkinson's Disease
NCT04277247Phase 3Unknown
- Sponsor
- University of Calgary
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in Parkinson's disease (PD), dystonia, sponsored by University of Calgary. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
Parkinson's disease (PD)dystonia
Beyond the preview
Go deeper on NCT04277247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277247.